News & Progress

Press Releases

February 12, 2020
Palleon Pharmaceuticals Appoints Li Peng, Ph.D., as Chief Scientific Officer
November 19, 2019
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE-Her2 and Anti-Siglec-9 Antibody Programs at the 11th Annual Protein & Antibody Engineering Summit
November 07, 2019
Palleon Pharmaceuticals to Present Preclinical Data on EAGLE and HYDRA Platforms at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
February 06, 2019
Palleon Pharmaceuticals Announces Successful Defense of European Patent

View All Press Releases

In the News

February 14, 2020
Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
Endpoints
February 10, 2020
Beyond PROTACs and the proteasome: broadening the TAC toolbox
BioCentury
January 31, 2020
Carolyn Bertozzi’s glycorevolution
Chemical & Engineering News
January 06, 2020
SIGLECs go from homing beacons to next-generation checkpoints
BioCentury

Publications & Posters

Poster
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118
Poster
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273
Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019.
Poster
A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer
American Association for Cancer Research, April 2019, Poster #LB-109

View All Publications & Posters

Social Media